American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1115-1121 , December 2008

Temporal Trends in Red Blood Transfusion Among US Dialysis Patients, 1992-2005

  • Hassan N. Ibrahim, MD, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • University of Minnesota, Minneapolis, MN
    • Corresponding Author InformationAddress correspondence to Hassan N. Ibrahim, MD, MS, Division of Renal Diseases and Hypertension, University of Minnesota, 717 Delaware St SE, Ste 353, MMC 1932, Minneapolis, MN 55414
    • ,
  • Areef Ishani, MD, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • University of Minnesota, Minneapolis, MN
    • ,
  • Robert N. Foley, MB

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Haifeng Guo, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Jiannong Liu, PhD

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Allan J. Collins, MD, FACP

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • University of Minnesota, Minneapolis, MN

Received 25 February 2008 ,Accepted 7 July 2008.

References 

  1. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med. 1997;336:933–938
  2. Higgins MR, Grace M, Ulan RA, et al. Anemia in hemodialysis patients. Arch Intern Med. 1977;137:172–176
  3. Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. Kidney Int. 2004;65:757–767
  4. Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther. 2003;25:1786–1805
  5. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14:14–18
  6. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  8. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  9. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?. Kidney Int. 2007;72:806–813
  10. Amgen. Aranesp. [package insert] Thousand Oaks, CA: Amgen; 2007;
  11. Goodnough LT, Strasburg D, Riddell J, et al. Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients?. Clin Nephrol. 1994;41:303–307
  12. US Renal Data System. USRDS 1995 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995;
  13. Besarbe A, Bolton K, Browne J, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1989;339:584–590
  14. Hakim RM, Stivelman JC, Schulman G. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis. 1987;10:293–299
  15. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int. 2005;18:532–540

 Originally published online as doi:10.1053/j.ajkd.2008.07.022 on September 29, 2008.

PII: S0272-6386(08)01193-1

doi: 10.1053/j.ajkd.2008.07.022

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1115-1121 , December 2008

Article Tools

* Image Usage & Resolution